William Blair analyst Margaret Kaczor reiterated a Buy rating on CVRx (CVRX – Research Report) on January 18 and set a price target of $17.62.

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether ...

William Blair has upgraded CVRx (NASDAQ:CVRX) to outperform from market perform, citing utilization improvements and ...

Craig-Hallum raised the firm’s price target on CVRx (CVRX) to $22 from $20 and keeps a Buy rating on the shares. CVRx posted a modest beat in ...

The market expects CVRx (CVRX) to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook is ...

CVRx (NASDAQ:CVRX – Get Free Report) had its price objective increased by stock analysts at Craig Hallum from $20.00 to $22.00 in a report released on Friday,Benzinga reports. The brokerage currently ...

Fourth quarter revenue expected to be $15.2 million to $15.3 million, representing growth of 35%Full year revenue expected to ...

CVRx anticipates a 35% increase in Q4 2024 revenue and a 30% increase in FY24 revenue, with shares down 1.55% premarket.

CVRx, Inc. (NASDAQ:CVRX), a biomedical devices company with a market capitalization of $331.2 million specializing in the treatment of heart failure and hypertension through its innovative ...

CVRx (NASDAQ:CVRX) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The following table provides a quick overview of ...